All Blogs
Mar 05, 2026
Abbott’s New CardioMEMS™ Remote Monitoring Reader Gains FDA Approval; Mobia Medical and Sanford Health Secure FDA Approval for Vivistim Stroke Therapy; Johnson & Johnson Introduces Cereglide™ 42, Cereglide™ 57, and Innerglide™ 7 to Strengthen Catheter Portfolio; Baird Medical Advances Worldwide Registration of AI-Based Surgical Technology; THINK Surgical Achieves First Clinical Use of the TMINI Miniature Robotic System Paired With the Stryker Triathlon Knee System; Monteris Medical Reports Study Linking NeuroBlate® Laser Ablation to Stronger Immunotherapy Response in Recurrent High-Grade Brain Tumors
Abbott’s Next‑Generation Cardiomems™ Remote Heart Failure Monitoring Reader Received FDA Approval to Enhance Patient Experience and Help Detect Disease Progression On 27 February 2026, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved the company’s CardioMEMS™ HERO device, a ne...
Read More...
Mar 04, 2026
Foot and Ankle Devices: Transforming Orthopedic Care Through Innovation
The human foot and ankle constitute a complex mechanical structure containing 26 bones, 33 joints, and over 100 muscles, tendons, and ligaments. Given its role as the primary interface between the body and the ground, it is subject to immense biomechanical stress and a high incidence of pathology. Historically, foo...
Read More...
Mar 03, 2026
Merck’s WELIREG Advances with FDA Priority Review in Early RCC Supported by Compelling DFS Evidence; Roche’s Fenebrutinib Delivers Another Phase III Victory; Positive CHMP Opinion Paves Way for Novartis’ Remibrutinib in CSU Treatment; Pfizer’s BRAFTOVI Regimen Gains FDA’s Full Nod for Initial Treatment of Metastatic Colorectal Cancer; VYVGART Achieves Positive Results in Phase 3 ADAPT OCULUS Trial
Merck’s WELIREG Secures Priority FDA Review for Adjuvant Treatment in Early RCC Driven by Pivotal DFS Improvement Merck announced landmark results from its Phase 3 LITESPARK-022 trial, which evaluated the combination of KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) as an adjuvant treatment for patients with ...
Read More...
Mar 02, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...
Read More...
Feb 26, 2026
Galderma Secures Triple Approval for Its New Cutting-Edge Restylane® Syringe Across the European Union, United States, and Canada; 4WEB Medical Secures FDA 510(k) Clearance for New SI Joint Truss System; Medtronic Debuts MiniMed Go Smart Insulin-Delivery System Featuring Simplera Sensor in the EMEA Region; Olympus Expands Labeling to Include Pediatric Use for Two Single-Use Bronchoscopes; Neurent Medical Reports Positive Randomized Controlled Trial Outcomes for the NEUROMARK® System; Envoy Medical Approaches Final Enrollment Phase for Its Fully Implanted Acclaim Cochlear Implant Trial
Galderma Announced Triple Approval of new state-of-the-art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics On February 25, 2026, Galderma announced that regulatory authorities in the EU, the U.S., and Canada had approved a new...
Read More...
Feb 27, 2026
Postoperative Ileus Treatment: Innovation Lag in a High-Burden Market
Summary In 2024, the 7MM reported an estimated 772K new cases of postoperative ileus. FDA-approved treatment options include metoclopramide (REGLAN), neostigmine (PROSTIGMIN), and alvimopan (ENTEREG), all of which face generic competition, with alvimopan losing market exclusivity in 2024. The development ...
Read More...
Feb 25, 2026
Electrophysiology Devices: The Future of Cardiac Arrhythmia Management
Cardiac electrophysiology is a specialized branch of cardiology that focuses on the heart's electrical system and the diagnosis and treatment of heart rhythm disorders, known as arrhythmias. The field has evolved from simple diagnostic recordings to a highly sophisticated discipline that utilizes robotics, advanced...
Read More...
Feb 24, 2026
Gilead Sciences to Acquire Arcellx in Strategic Move to Accelerate Anito-cel Development; Novo Nordisk Faces Setback as CagriSema Underwhelms Against Rival Therapy in Trial; Vanda Pharmaceuticals Secures FDA Approval for BYSANTI; All-oral Calquence + venetoclax Combo Clears in the US for First-line Treatment of CLL; Merck’s ENFLONSIA Demonstrates Strong Protection Against Severe RSV in Young Children Over Consecutive Seasons
Gilead Sciences Announces Acquisition of Arcellx to Advance Long-Term Growth of Anito-cel Gilead Sciences announced a definitive agreement to acquire Arcellx, a clinical-stage biotechnology company, in a strategic move to strengthen its leadership in cell therapy and oncology innovation. The acquisition builds o...
Read More...
Feb 23, 2026
Bone Marrow Failure: The Silent Global Crisis Driving a New Era of Therapeutic Innovation
Summary In 2024, the 7MM reported approximately 35,000 incident BMF cases, highlighting the persistent clinical burden and the ongoing need for earlier diagnosis and more effective treatment strategies. ROMIPLATE has made notable regulatory progress in Japan, its only approved market for aplastic anemia, ex...
Read More...
Feb 20, 2026
Tumor‑Infiltrating Lymphocyte (TIL) Therapies: Redefining Cell Therapy for Solid Tumors
Summary TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prosta...
Read More...